Journal of vascular and interventional radiology : JVIR · 2025
Material Matters: A Systematic Review and Meta-Analysis of the Effectiveness of Different Embolic Agents in Middle Meningeal Artery Embolization.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Mitesh, Saha Abhisek, Gupta Abhishek, Gupta Madan Mohan, Shaw Manish, Singhal Praveen, Sharma Sanjiv
Аннотация
PURPOSE: To compare the effectiveness and safety of different embolizing agents used in middle meningeal artery embolization (MMAE) for the treatment of chronic subdural hematoma.
MATERIALS AND METHODS: A literature search of PubMed, Cochrane Library, Scopus, and Google Scholar (up to 2024) included studies reporting MMAE outcomes for chronic subdural hematoma (cSDH). Study quality was evaluated using the Joanna Briggs Institute and Risk of Bias 2 (RoB 2) tools. Pooled data were analyzed with random-effects models, with heterogeneity assessed via the I2 statistic. Statistical significance was set at P < .05.
RESULTS: Of 997 articles screened, 33 studies (2013-2024) with 1,818 patients (mean age, 74.2 years [SD ± 11]; median follow-up, 3 months) were included. The pooled recurrence rate after MMAE was 0.07 (95% confidence interval, 0.05-0.10). By embolic agent, recurrence rates were the following: (a) polyvinyl alcohol (PVA), 0.07; (b) n-butyl cyanoacrylate (nBCA), 0.05; and (c) ethylene vinyl alcohol copolymer (EVOH), 0.07. Periprocedural complication rates were low: PVA, 0.02; nBCA, 0.01; EVOH, 0.00; and overall rate, 0.01. Favorable clinical and radiologic outcomes were observed in 81% and 84% of cases, respectively.
CONCLUSIONS: MMAE is effective for cSDH, offering low recurrence and complication rates with favorable clinical and radiologic outcomes. All embolic agents demonstrated promising effectiveness and safety profiles.
MATERIALS AND METHODS: A literature search of PubMed, Cochrane Library, Scopus, and Google Scholar (up to 2024) included studies reporting MMAE outcomes for chronic subdural hematoma (cSDH). Study quality was evaluated using the Joanna Briggs Institute and Risk of Bias 2 (RoB 2) tools. Pooled data were analyzed with random-effects models, with heterogeneity assessed via the I2 statistic. Statistical significance was set at P < .05.
RESULTS: Of 997 articles screened, 33 studies (2013-2024) with 1,818 patients (mean age, 74.2 years [SD ± 11]; median follow-up, 3 months) were included. The pooled recurrence rate after MMAE was 0.07 (95% confidence interval, 0.05-0.10). By embolic agent, recurrence rates were the following: (a) polyvinyl alcohol (PVA), 0.07; (b) n-butyl cyanoacrylate (nBCA), 0.05; and (c) ethylene vinyl alcohol copolymer (EVOH), 0.07. Periprocedural complication rates were low: PVA, 0.02; nBCA, 0.01; EVOH, 0.00; and overall rate, 0.01. Favorable clinical and radiologic outcomes were observed in 81% and 84% of cases, respectively.
CONCLUSIONS: MMAE is effective for cSDH, offering low recurrence and complication rates with favorable clinical and radiologic outcomes. All embolic agents demonstrated promising effectiveness and safety profiles.